Enarodustat (formerly known as JTZ951; JTZ-951; trade name in Japan: Enaroy), the hydrochloride salt of Enarodustat, is a potent and orally bioavailable inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH) that has been approved in 2020 for use in Japan for the treatment of anemia associated with chronic kidney disease (CKD).

纯度：≥98%

CAS：1262131-60-1